Orgenesis Inc
Change company Symbol lookup
Select an option...
ORGS Orgenesis Inc
ABCB Ameris Bancorp
LKNCY Luckin Coffee Inc
DLTA Delta Oil & Gas Inc
SIEB Siebert Financial Corp
CUBI-F Customers Bancorp Inc
HUN Huntsman Corp
IART Integra Lifesciences Holdings Corp
R Ryder System Inc
AAPL Apple Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Orgenesis Inc. is a global biotech company that is operating to unlock the potential of cell and gene therapies (CGTs). The Company is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). It has developed a Point of Care Platform (POCare Platform) comprised of three enabling components, which includes a pipeline of POCare advanced therapies that are designed to be processed and produced, automated closed POCare technology systems, and a worldwide network of POCare research institutes and hospitals (POCare Network). Its products in clinical use include KYSLECEL, Tissue Genesis Icellator for Cell Assisted Lipotransfer, Cartil-S Autologous products for the treatment of osteoarthritis, and Chondroseal Autologous products for the treatment of cartilage defects.

Postmarket

Last Trade
Delayed
$1.84
-0.03 (-1.60%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.87
Day's Change
0.07 (3.89%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
1.89
Day's Low
1.76
Volume
(Light)
Volume:
11,634

10-day average volume:
62,585
11,634

Company Profile

Orgenesis Inc. is a global biotech company that is operating to unlock the potential of cell and gene therapies (CGTs). The Company is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). It has developed a Point of Care Platform (POCare Platform) comprised of three enabling components, which includes a pipeline of POCare advanced therapies that are designed to be processed and produced, automated closed POCare technology systems, and a worldwide network of POCare research institutes and hospitals (POCare Network). Its products in clinical use include KYSLECEL, Tissue Genesis Icellator for Cell Assisted Lipotransfer, Cartil-S Autologous products for the treatment of osteoarthritis, and Chondroseal Autologous products for the treatment of cartilage defects.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
1.24x
Price/Book (MRQ)
1.19x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

July 2022
Current Month
169.9K
Previous Month
204.6K
Percent of Float
0.75%
Days to Cover
6.5704 Days

Share Information

ORGS is in a share class of common stock
Float
22.6M
Shares Outstanding
24.8M
Institutions Holding Shares
27
15.13%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Vered CaplanChmn.
  • Neil T. ReithingerCFO
  • Efrat Assa- KunikOther
  • Yaron Adler
  • Ashish Nanda

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.